D’Ambrosio, Enrico
Pergola, Giulio
Pardiñas, Antonio F.
Dahoun, Tarik
Veronese, Mattia
Sportelli, Leonardo
Taurisano, Paolo
Griffiths, Kira
Jauhar, Sameer
Rogdaki, Maria
Bloomfield, Michael A. P.
Froudist-Walsh, Sean
Bonoldi, Ilaria
Walters, James T. R.
Blasi, Giuseppe
Bertolino, Alessandro
Howes, Oliver D.
Funding for this research was provided by:
Academy of Medical Sciences (SBF005\1083)
NIHR Maudsley Biomedical Research Centre
Wellcome Trust (215747/Z/19/Z, 094849/Z/10/Z)
Ministero dell'Università e della Ricerca
Medical Research Council (MC_U120097115)
Article History
Received: 3 March 2022
Accepted: 11 July 2022
First Online: 23 July 2022
Competing interests
: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. ODH is a part-time employee of H. Lundbeck A/S and has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angelini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Rand, Recordati, Roche and Viatris/Mylan. Neither ODH nor his family have holdings/a financial stake in any pharmaceutical company. ODH has a patent for the use of dopaminergic imaging. JTRW is an investigator on a grant from Takeda Pharmaceuticals Ltd. to Cardiff University, for a project unrelated to the work presented here. The other authors have nothing to declare.